Cancer Innovation最新文献

{"title":"Expert Consensus on the Clinical Application of Poly ADP Ribose Polymerase Inhibitors in Breast Cancer (2025 Edition)","authors":"Fei Ma,&nbsp;Binghe Xu,&nbsp;China Anti-Cancer Association Committee on Clinical Research of Anticancer Drugs, National Expert Committee on Monitoring Clinical Application of Antineoplastic Drugs, Breast Cancer Expert Committee of National Cancer Quality Control Center, Expert Committee on Chemotherapy Quality Control of Beijing Cancer Treatment Quality Control and Improvement Center","doi":"10.1002/cai2.70062","DOIUrl":"https://doi.org/10.1002/cai2.70062","url":null,"abstract":"<p>Breast cancer represents a major threat to women's health in China. Its continuously rising incidence contributes to a growing disease burden, thereby creating a critical demand for novel and effective therapeutic strategies. In recent years, poly ADP-ribose polymerase (PARP) inhibitors, as a novel class of anti-tumor drugs targeting the DNA damage repair pathway, have demonstrated remarkable efficacy in treating breast cancer with <i>BRCA1/2</i> mutations. By selectively inhibiting DNA repair in tumor cells, these agents induce a “synthetic lethality” effect, offering a new option for precision therapy. Currently, PARP inhibitors such as Olaparib and Fluzoparib have been approved for clinical use. This consensus, based on the latest evidence-based medical data, provides guidance on the standardized application and safety management of PARP inhibitors in breast cancer treatment, aiming to serve as a reference for clinical practice.</p>","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":"5 3","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cai2.70062","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148174745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":"5 3","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148090011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Practice-Changing Advances in Systemic Therapies Shaping the Landscape of Lung Cancer in 2025.","authors":"Zhenyu Zhou, Wanting Gao, Molly S C Li, Qing Zhou","doi":"10.1002/cai2.70064","DOIUrl":"10.1002/cai2.70064","url":null,"abstract":"<p><p>With the rapid advancement of molecular profiling and precision therapeutics, targeted and immunotherapeutic strategies have irrevocably reshaped the pharmacological management for both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Overall mortality from lung cancer has continued its downward trend over the past decade, and this decline has accelerated, largely driven by advances in early detection and curative-intent surgeries. In parallel, the systemic therapies have undergone a dramatic evolution with the integration of, for example, antibody-drug conjugates (ADCs) and bispecific antibodies (BsAbs). The year 2025 marks a period of significant progress in lung cancer treatment, characterized by groundbreaking therapeutic successes across all disease stages and subtypes. This comprehensive review synthesizes pivotal evidence presented at key oncology forums in 2025 to delineate the substantially evolved clinical landscape.</p>","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":"5 3","pages":"e70064"},"PeriodicalIF":2.0,"publicationDate":"2026-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13238848/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148202004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":"5 3","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148075392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multiple Primary Malignancies in Patients With Gastric Cancer: A Retrospective Study in National Cancer Center of China.","authors":"Guiling Zhu, Yutong Li, Bingzhi Wang, Liyan Xue, Yuchen Jiao, Xiaobing Wang, Chunxia Du","doi":"10.1002/cai2.70063","DOIUrl":"10.1002/cai2.70063","url":null,"abstract":"<p><strong>Background: </strong>Gastric cancer (GC) is a prevalent malignancy in China, posing significant health challenges. The persistently high tumor incidence and the rising number of tumor survivors may elevate the risk of multiple primary malignancies (MPMs) in GC patients.</p><p><strong>Methods: </strong>We conducted a retrospective study involving 11,045 patients diagnosed with gastric adenocarcinoma at National Cancer Center of China between 2010 and 2017. A 6-month interval distinguished synchronous MPMs (SMPMs) from metachronous MPMs (MMPMs).</p><p><strong>Results: </strong>Of all GC patients, 443 (4.01%) had MPM, with 75.85% being males and an average age of 60 at initial diagnosis. Among the MPM cases, 415 (93.68%) had two primary cancers (53.98% synchronous and 46.02% metachronous), 27 (6.09%) had three, and 1 (0.23%) had four, totaling 472 extra gastric cancer sites. Esophageal, colorectal, and lung cancers were the most prevalent concomitant malignancies, with esophageal cancer more frequent in synchronous cases and breast cancer (observed only in females) more frequent in metachronous cases (both <i>p</i> < 0.001). In patients with two primary cancers, the SMPM subset included more males (<i>p</i> < 0.001), with higher rates of smoking (<i>p</i> = 0.012), alcohol consumption (<i>p</i> < 0.001), and higher T stage at first diagnosis (<i>p</i> < 0.001). The MMPM subset included more females (<i>p</i> < 0.001), was younger at first diagnosis (<i>p</i> < 0.001), and more frequently underwent surgery after first diagnosis (<i>p</i> < 0.001).</p><p><strong>Conclusions: </strong>MPM occurring in patients with GC predominantly involve the esophagus, colorectum, and lung. Elderly male patients with smoking or alcohol use represent a higher-risk group and warrant vigilant surveillance. This study provides a clinical and epidemiologic basis for future research on MPM in GC.</p>","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":"5 ","pages":"e70063"},"PeriodicalIF":2.0,"publicationDate":"2026-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13167386/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147944442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":"5 3","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148099213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rationale and Trial Design of DAWNA-FES Trial: Single-Arm Phase II Study of Endocrine Therapy With Dalpiciclib After Progression on CDK4/6 Inhibition Based on [¹⁸F]FES PET/CT in Patients With HR+/HER2- Advanced Breast Cancer.","authors":"Ru Yao, Yang Qu, Zhixin Hao, Ying Xu, Jiahui Zhang, Jie Lian, Lu Gao, Songjie Shen, Feng Mao, Bo Pan, Qiang Sun, Li Huo, Yidong Zhou","doi":"10.1002/cai2.70058","DOIUrl":"10.1002/cai2.70058","url":null,"abstract":"<p><strong>Background: </strong>Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have become a cornerstone in the first-line management of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer. Despite their clinical efficacy, most patients eventually experience disease progression, and optimal treatment strategies following CDK4/6 inhibitor resistance remain unclear. Emerging evidence suggests that switching endocrine therapy (ET) while continuing cyclin inhibition may provide additional clinical benefit. Dalpiciclib, a selective CDK4/6 inhibitor, in combination with physician-selected ET, represents a potential option in this setting. Concurrently, 16α-[¹⁸F]fluoro-17β-estradiol ([¹⁸F]FES) PET/CT, a novel imaging modality targeting estrogen receptors (ER), enables non-invasive, whole-body assessment of ER expression in metastatic lesions, offering a personalized approach to treatment selection.</p><p><strong>Methods: </strong>This is a prospective, single-center, single-arm Phase II clinical trial evaluating the efficacy and safety of dalpiciclib plus ET in HR+/HER2- advanced breast cancer patients who progressed on prior CDK4/6 inhibitor therapy. Forty eligible patients with confirmed metastases and at least one [¹⁸F]FES-positive lesion will be enrolled. Participants will receive dalpiciclib combined with ET as determined by the treating physician. The primary endpoint is progression-free survival (PFS). Secondary endpoints include objective response rate (ORR), disease control rate (DCR), and overall survival (OS).</p><p><strong>Discussion: </strong>Beyond evaluating efficacy, this single-center phase II trial will provide practical insight into the feasibility of [¹⁸F]FES PET/CT-guided patient selection, including standardized imaging workflows and multidisciplinary implementation in routine clinical research. Positive outcomes may support a personalized, imaging-guided strategy to prolong disease control after prior CDK4/6 inhibitor progression.</p><p><strong>Ethical approval and trial registration: </strong>Approved by the Ethics Committee of Peking Union Medical College Hospital (Approval number: K3629); registered at ClinicalTrials. gov (NCT05613270).</p>","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":"5 3","pages":"e70058"},"PeriodicalIF":2.0,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13129906/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147825597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":"5 3","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148099212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":"5 2","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148086314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Consensus on Human Epidermal Growth Factor Receptor 2 Overexpression Testing in Pan-Tumor.","authors":"Zhe Wang, Lin Chen, Wei Rao, Baoshan Cao, Muyan Cai, Xiangshan Fan, Yuan Ji, Yuan Li, Yan Song, Yan Sun, Yu Sun, Chunyan Wu, Qingxin Xia, Yanfeng Xi, Liyan Xue, Rutie Yin, Han Liang, Jianming Ying","doi":"10.1002/cai2.70060","DOIUrl":"10.1002/cai2.70060","url":null,"abstract":"<p><p>Human epidermal growth factor receptor 2 (HER2) is a key biomarker and therapeutic target in several malignancies, including breast, gastric, and other solid tumors. Recent advancements in cancer molecular profiling and the Food and Drug Administration's approval of trastuzumab deruxtecan for HER2-positive pan-tumor indications have highlighted the broader relevance of HER2 alterations across diverse cancers. However, the lack of standardized guidelines for HER2 testing in a pan-tumor context creates variability in clinical practice, hindering the optimal implementation of HER2-targeted therapies beyond traditional indications. To address this gap, a multidisciplinary panel of Chinese experts has developed a consensus providing comprehensive recommendations on diagnostic strategies, testing methodologies, and clinical applications of HER2 overexpression detection. By establishing a unified framework for HER2 overexpression assessment, this consensus aims to enhance the precision of HER2 testing, optimize patient selection for targeted therapies, and improve clinical outcomes across a wide spectrum of HER2 overexpression malignancies.</p>","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":"5 2","pages":"e70060"},"PeriodicalIF":2.0,"publicationDate":"2026-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13098049/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147793802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}